MSC Exosomes for Traumatic Brain Injury (TBI) | BioRegenEx
Traumatic brain injury is a major cause of death and disability in the United States, affecting 1.5–2 million Americans annually. MSC-derived exosomes are being intensively studied as a neuroprotective and neuroregenerative tool following TBI — with published research demonstrating meaningful effects on inflammation, cell survival, and functional recovery.
Why TBI Demands New Therapeutic Approaches
The secondary injury cascade following TBI — involving neuroinflammation, oxidative stress, blood-brain barrier disruption, and programmed cell death — unfolds over hours to weeks after the primary impact. No approved pharmacological intervention currently targets this cascade effectively. This treatment gap has driven significant research interest in MSC-derived exosomes, which deliver a complex mix of neuroprotective molecules that address multiple aspects of secondary injury simultaneously.
Published Research: MSC Exosomes and TBI
- MSC-derived exosomes improve outcome after TBI in rodent models (PubMed)
- Exosome treatment reduces neuroinflammation and promotes angiogenesis after TBI (PubMed)
- Intravenous delivery of MSC exosomes reduces neuronal loss following controlled cortical impact (PubMed)
- View all TBI and neurological research in the BioRegenEx Research Library →
Mechanisms of Action in TBI
- BBB protection and repair: Exosomes reduce tight junction protein loss, helping restore blood-brain barrier integrity after injury.
- Microglial modulation: Shifting activated microglia from pro-inflammatory M1 to anti-inflammatory M2 phenotype reduces secondary damage.
- Axonal repair signals: Exosome cargo includes miRNAs that promote axonal outgrowth and remyelination in injured white matter tracts.
- Edema reduction: Studies show exosome treatment reduces post-traumatic cerebral edema, a major source of secondary injury.
Applications in Physician Practice
BioRegenEx works with neurologists, neurosurgeons, sports medicine physicians, and integrative medicine practitioners exploring regenerative approaches to TBI. Our physician portal provides access to research-grade MSC exosomes, full regulatory documentation, and clinical protocol support.
Partner With BioRegenEx
Join licensed physicians across the US who use BioRegenEx research-grade MSC exosomes in their regenerative medicine practice.
Supporting Research & Related Applications
📚 Browse the MSC Exosome Research Library (102+ studies) →
- MSC Exosomes for Stroke Recovery →
- MSC Exosomes for Alzheimer’s & Parkinson’s →
- MSC Exosomes for Spinal Cord Injury →
Sourcing MSC exosomes for your practice? Partner with BioRegenEx →
Research-use-only. Not intended to diagnose, treat, cure, or prevent any disease.
Frequently Asked Questions
What are MSC-derived exosomes?
Mesenchymal stem cell (MSC)-derived exosomes are nanoscale extracellular vesicles (roughly 30–150 nm) that carry signaling cargo such as proteins, lipids, and microRNA. They are cell-free (acellular) — not stem cells — and are studied in research for their role in cell-to-cell communication. BioRegenEx supplies characterized, research-use-only MSC exosomes with per-lot documentation.
What does research explore about MSC exosomes and traumatic brain injury?
Preclinical research has examined MSC-derived exosomes for neuroprotective and neuroinflammatory signaling in brain-injury models. This is early-stage research, not proof of clinical benefit. The literature is indexed in our Exosome Research Library.
Are MSC exosomes approved to treat TBI?
No. MSC-derived exosomes are not approved by the FDA to diagnose, treat, cure, or prevent this or any condition, and are supplied for research use only (RUO). Nothing here is a treatment claim.
Provided for research and educational purposes. Materials are research-use-only and are not intended to diagnose, treat, cure, or prevent any disease.